Tissue Source Site (TSS) Name: ______ TSS Identifier: _____ TSS Unique Patient #: ___


V4.50

Completed By: ___

_____ Completion Date (MM/DD/YYYY): ___

Form Notes: Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.

Question #	Data Element Label	Data Entry Alternatives	CDE ID With Working Instructions
1	Has this TSS received permission from NCI to provide time intervals as a substitute for requested dates on this form?*	☐ Yes ☐ No	Please note that time intervals must be recorded in place of dates where designated throughout this form if you have selected "yes" in the box to the left. Note 1: Provided time intervals must begin with the date of initial pathological diagnosis (i.e. biopsy or resection). Note 2: Only provide interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.
2	Invasive Adenocarcinoma Diagnosis Indicator	Yes No	3027106 Confirm that the pancreas tumor sample being submitted to TCGA is an invasive adenocarcinoma.
3	Histological Subtype*	 Pancreas, Adenocarcinoma Ductal Type Pancreas, Colloid (mucinous non-cystic) Carcinoma Pancreas, Hepatoid Carcinoma Pancreas, Medullary Carcinoma Pancreas, Signet Ring Cell Carcinoma Pancreas, Undifferentiated Carcinoma Pancreas, Carcinoma w/Osteoclast-like Giant Cells Pancreas, Adenocarcinoma, Other Subtype (please specify below) 	3081934 Indicate the histologic subtype for the pancreas tumor sample being submitted to TCGA. Note 1: Cholangiocarcinoma and Mixed Histologic Subtypes Are Excluded For This Tumor Type. Note 2: Tumors originating in the bile duct, ampulla and duodenum are excluded.
4	Other Histological Subtype		3124492 If the histological subtype is not included in the provided list, specify the histological subtype of the pancreatic adenocarcinoma that is being submitted to TCGA.
5	Tumor Type*	Primary	3288124 Confirm that the tumor being submitted to TCGA is a primary untreated malignant biospecimen.
6	Anatomic Site of Frozen Biospecimen (check all that apply)*	 Pancreatic Head Pancreatic Tail Pancreatic Body Other (please specify) 	3421413 Indicate the anatomic site of the frozen tumor submitted for TCGA. Note: Tumors originating in the bile duct, ampulla and duodenum are excluded.
7	Other Anatomic Site of Frozen Biospecimen		3320289 If the anatomic site of the frozen biospecimen is not included in the provided list, specify the other anatomic site of the frozen tumor submitted to TCGA.
8	Confirmed Intraductal Papillary Mucinous Neoplasm (IPMN) Diagnosis on Pathology Report	□ Yes □ Unknown	2483560 Indicate if the pathology report states that the pancreas tumor was associated with IPMN.
9	Confirmed Mucinous Cystic Neoplasm (MCN) Diagnosis on Pathology Report	Yes Unknown	3407712 Indicate if the pathology report states that the pancreas tumor was associated with MCN
Date of Sample Procurement			
10	Month of Sample Procurement	(MM)	3008197 Provide the month of the procedure performed to obtain the malignant tissue submitted for TCGA.
11	Day of Sample Procurement		3008195 Provide the day of the procedure performed to obtain the malignant tissue submitted for TCGA.



V4.50



Question #	Data Element Label	Data Entry Alternatives	CDE ID With Working Instructions
	Is Tumor Sample being		3288488
24	submitted for Laser Cryo	Yes	Indicate if the tumor sample being submitted is to be processed
21	Enrichment (LCE)		using Laser Cryo Enrichment (LCE).
	processing?*		Note: Most pancreatic adenocarcinoma cases are not expected to be suitable for this technology.
			3081942
22	Was sample prescreened	Yes	Indicate whether the sample submitted to the BCR was
22	at site?*	□ No	prescreened at the TSS.
			3081944
		T Yes	Indicate whether a physical top slide for the sample submitted
23	Will Top Slide be		to the BCR will be shipped with the tissue sample.
	submitted to the BCR?*	No No	Note: Top slide definition-Slide cut directly from frozen
			biospecimen = mirror image of inked surface.
	Will Digital Slide Image		3081948
24	be submitted to the	Yes	Indicate whether a digital slide image for the sample submitted
	BCR?*		to the BCR will be shipped with the tissue sample.
			Note: Physical top slides are preferred.
25	Tunnen Identifien*		3288096
25	Tumor Identifier*		Provide the TSS unique tumor ID. If multiple pieces of tumor are submitted, each tumor needs a unique ID.
			3081946
26	Weight of Frozen Tumor*		Provide the weight of the tumor sample submitted for TCGA.
20	Weight of 1102en runfor		Note: (0.2cm ³ (0.6cm * 0.6cm * 0.6cm) = ~200mg
			2841225
			Provide the percent of tumor nuclei for the sample submitted
27	Tumor Nuclei %*		for TCGA.
			Note: Check with the BCR to confirm the current acceptable
			TCGA metrics.
			2841237
			Provide the percent of necrosis for the sample submitted for
28	Tumor Necrosis %*		TCGA.
			Note: Check with the BCR to confirm the current acceptable TCGA metrics.
			2321277
29	Top Slide / Digital Slide		Provide the slide ID for the physical top slide OR the digital slide
	Image ID #*		image being sent to the BCR.
Normal Inform	mation: A normal control mu	st be present to qualify	
			3288138
30	Normal 1 Identifier		Provide the TSS unique normal ID. If multiple normal control
			samples are submitted, each normal control needs a unique ID.
		Whole Blood	3081936
	Type(s) of Normal Control*		Indicate the type of normal control submitted for this case.
		Buffy Coat	Note 1: Whole blood is the preferred normal.
		Lymphocytes	Note 2: Normal tissue is accepted from an adjacent organ if
31			the normal tissue is > 2cm from the tumor. All normal tissue
		Extracted DNA from Blood	must be reviewed by a pathologist to ensure no evidence of
		Normal Tissue from Duodenum	tumor cells. Note 3: Normal tissue from pancreas is only allowed if a
		Normal Tissue from Other Anatomic Site	second source of germline material is provided (e.g. DNA from
			blood, tissue from other organ).
	Other Anatomic Site of	(specify below)	3288189
32	Non-Neoplastic Control		If the normal control type is normal tissue from an adjacent
52	Tissue		organ, specify the site of the non-neoplastic control.
	Method of Normal	Blood Draw Excisional Biopsy	3288147
33	Sample Procurement	Surgical Resection Other Method	Indicate the procedure performed to obtain the normal sample
		(please specify below)	submitted for TCGA.
			3288151
34	Other Method of Normal		If the procedure performed to obtain the normal sample is not
	Sample Procurement		included in the provided list, specify the procedure.
			3088708
35	Proximity of Normal Tissue (from adjacent organ)	□ > 2 cm from the primary tumor	Confirm that the normal tissue being submitted from an
			adjacent organ is > 2cm from the primary tumor.
			Note 1: Adjacent normal tissue (>2 cm) from the pancreas is
	to Tumor		only accepted as part of the "double normal" study. In this situation, the blood normal and the pancreas normal may be

Question #	Data Element Label	Data Entry Alternatives	CDE ID With Working Instructions
			submitted with prior NCI approval.
			Note 2: Adjacent normal pancreas tissue (<2cm) and normal
			tissue of unknown proximity is not accepted for this tumor
			type.
Date of Norm	al Sample Procurement		2200405
36	Month of Normal Sample		3288195 Provide the month of the procedure performed to obtain the
	Procurement		normal control sample submitted for TCGA.
			3288196
37	Day of Normal Sample	(DD)	Provide the day of the procedure performed to obtain the
	Procurement		normal control sample submitted for TCGA.
	Year of Normal Sample		3288197
38	Procurement		Provide the year of the procedure performed to obtain the
			normal control sample submitted for TCGA.
			3288496
	Number of Days from		Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of
	Date of Diagnosis to Date		the procedure that produced the normal control sample
39	of Normal Sample		submitted for TCGA.
	Procurement		Note: Only provide Interval data if you have received
			permission from the NCI to provide time intervals as a
			substitute for requested dates on this form.
			3288185
40	Extracted DNA Quantity		If the normal control type is extracted DNA from blood, provide
			the quantity (μg) of the normal control sample sent to the BCR for TCGA.
			3288186
	Extracted DNA		If the normal control type is extracted DNA from blood, provide
41	Quantification Method		the quantification method of the normal control sample sent to
			the BCR for TCGA.
			3288187
42	Extracted DNA		If the normal control type is extracted DNA from blood, provide
	Concentration		the concentration (μ g/ μ L) of the normal control sample sent to
			the BCR for TCGA. 3288188
	Extracted DNA Volume		If the normal control type is extracted DNA from blood, provide
43			the volume (μ L) of the normal control sample sent to the BCR
			for TCGA.
			3288217
44	Normal Slide ID #		If the normal control type is normal tissue, provide the slide ID
			for the physical top slide OR the digital slide image of the
			normal control being sent to the BCR.
45	Name of Pathologist		3288225 Provide the name of the Pathologist that reviewed the top slide
45	Name of Pathologist		and provided the information for all previous sections.
			3288224
46	Date of Pathologist		Provide the date of the pathology prescreening review
	Review	,,,,,,,	performed by the TSS pathologist above.
			3288497
	Number of Days from Date of Diagnosis to Date of Pathological Review		Provide the number of days from the date the patient was
47			initially diagnosed pathologically with the disease to the date of
			the pathological review performed as part of the submission process for TCGA.
			Note: Only provide Interval data if you have received
			3288520
	Percent Tumor Nuclei meets TCGA metrics?*	Yes	Confirm that the malignant sample submitted to the BCR meets
48			the current tumor nuclei metrics for TCGA.
			Note: Check with the BCR to confirm the current acceptable
			TCGA metrics.
49			3288524 Confirm that the malignant sample submitted to the BCR meets
	Percent Tumor Necrosis	L Yes	the current necrosis metrics for TCGA.
.5	meets TCGA metrics?*	□ No	Note: Check with the BCR to confirm the current acceptable
			TCGA metrics.
	De-Identified Pathology	Yes	3288292
50	Report Submitted?*		Confirm that a de-identified pathology report will be sent to
		L No	BCR prior to or with the shipment of the physical samples.

V4.50



Oursetting #	Data Flare ant Later	Data Entry Altownstings	CDE ID With Working Instructions
Question #	Data Element Label	Data Entry Alternatives	CDE ID With Working Instructions 3288300
51	Is the histologic diagnosis on the CQCF (as determined by the TSS pathology review of the TCGA frozen section top slide) consistent with the histology listed in the final diagnosis on the pathology report?*	 Yes (skip related question below.) No * 	 Confirm that the diagnosis provided on this CQCF for the tumor sample being submitted to TCGA is consistent with the diagnosis found on the patient's pathology report for the tumor being sent to the BCR. Note: The diagnosis is considered to be consistent if at least one of the following criteria are met: Diagnosis on the CQCF is identical to the pathology report for the tumor being sent to the BCR. Diagnosis on the CQCF includes at least one of the subtypes listed on the pathology report and all subtypes on the pathology report are acceptable for TCGA. Diagnosis on the CQCF is "histology, NOS" (i.e. Adenocarcinoma, NOS) and the pathology report lists a specific subtype within the same histological group. Diagnosis on the CQCF indicates "Mixed Subtype" and the pathology report lists two or more acceptable subtypes, provided that percent subtype(s) meet applicable TCGA disease-specific requirements.Note: If "yes," skip related question below. The TSS needs approval from the NCI if the diagnosis on this form does not match the provided pathology report.
52	If the diagnosis on this form is not consistent with the provided pathology report, indicate the reason for the inconsistency.	 Macrodissection performed at TSS to select for region containing an acceptable TCGA diagnosis Pathology analysis at TSS determined a specific histological subtype different from original pathology report (see note at right) Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) 	3288315 If the diagnosis provided on this form is not consistent with the diagnosis found on the patient's pathology report for the tumor being submitted for TCGA, specify a reason for this inconsistency. Note: If a TSS pathology review of the TCGA committed sample resulted in a different histological subtype than what is documented on the pathology report, an amendment to the pathology report should be submitted when the sample is shipped to the BCR; or in the absence of an amended pathology report, the TSS must complete and submit an electronic copy of the "TCGA Pathologic Diagnosis Discrepancy Form."
53	History of Neo-adjuvant Treatment for Tumor Specimen Submitted for TCGA*	 No Radiation Prior to Sample Procurement Pharmaceutical Treatment Prior to Sample Procurement Both Radiation and Pharmaceutical Treatment Prior to Sample Procurement 	3382737 Indicate whether the patient received therapy for this cancer prior to sample procurement of the tumor submitted for TCGA. If the patient did receive treatment for this cancer prior to procurement, the TSS should contact the BCR for further instructions. Note: Systemic treatment and certain localized therapies (those administered to the same site as the TCGA submitted tissue) given prior to procurement of the sample submitted for TCGA are exclusionary.
54	Has the Patient Had Any Prior Cancer Diagnosed?*	 No History of Prior Malignancy History of Synchronous / Bilateral Malignancy 	3382736 Indicate whether the patient has a history of malignancies. Note: If the patient has any history of prior malignancies, including synchronous or bilateral malignancies, please complete an "Other Malignancy Form" for each malignancy diagnosed prior to the procurement of the tissue submitted for TCGA.
55	Consent Status*	Consented Exemption 4 Deceased Waiver	3288361 Indicate whether the patient was formally consented, consented by death, or if the case has an exemption or waiver for consent. Note: Either the Date of Consent or the Date of Death must be provided to qualify.
Date of Conse	ent		
56	Month of Consent	(MM)	3081955 If the patient was formally consented, provide the month of consent.
57	Day of Consent	(DD)	3081957 If the patient was formally consented, provide the day of consent.
58	Year of Consent		3081959 If the patient was formally consented, provide the year of consent.

Question #	Data Element Label	Data Entry Alternatives	CDE ID With Working Instructions
59	Number of Days from Date of Diagnosis to Date		3288498 If the patient formally consented, provide the number of days
	of Consent		from the date the patient was diagnosed with the disease described on this form to the date of the patient's formal consent.
Date of Death	1		•
60	Month of Death	(MM)	2897026
			If the patient consented by death, provide the month of death. Note: If the patient formally consented prior to death, only
			supply the date the patient consent.
61	Day of Death		2897028
			If the patient consented by death, provide the day of death
62	Year of Death		2897030 If the patient consented by death, provide the year of death.
63	Number of Days from Date of Diagnosis to Date of Death		3288499
			If the patient consented by death, provide the number of days
			from the date the patient was diagnosed with the disease
			described on this form to the date of the patient's death.
			Note: If the patient formally consented prior to death, do not
			answer this question only answer the question above that asks
			for the number of days between the date of diagnosis and the
			date of the patient consent.

Comments:

Principal Investigator Name: _____

Principal Investigator Signature:

Date Signed (MM/DD/YYYY):

V4.50